acceler relief novel approach treat acut pain
initi coverag acelrx outperform rate target price see
uniqu specialti pharmaceut compani well-posit captur market share
innov sublingu opioid treatment acut pain technolog valid
two product dsuvia zalviso main valu driver dsuvia
sufentanil formul dissolv sublingu tablet single-dos applic approv
us eu treatment moderate-to-sever acut pain certifi medic
supervis set us launch expect later month feedback physician expert
suggest signific interest util product lower cost increas patient throughput
improv patient satisfact emerg room post-op set compani
led solid team strong experi acut pain space suffici cash hand
fund current activ
invest posit includ dsuvia shown strong efficaci safeti especi
compar iv opioid technolog platform valid opinion leader kol
state allow improv patient satisfact also increas patient throughput
lower cost specif risk mitig plan place lower risk addict divers
compar iv/or opioid public support dsuvia fda commission
depart defens given drug uniqu properti
invest risk includ commercial-stag specialti pharmaceut compani
expect profit continu basi need like rais cash
believ peak sale dsuvia could higher street expect disappoint
accept dsuvia hospit pharmaci therapeut committe physician
could significantli affect acrx outlook given nearli revenu expect
dsuvia
catalyst dsuvia uptak earn potenti zalviso nda submiss
valuat target price base dcf valuat use discount rate significantli
higher us major pharma large-cap specialti pharma compani forecast discount
cash flow termin growth rate thereaft
analyst us disclosur credit suiss seek busi compani cover research report result investor awar firm may
conflict interest could affect object report investor consid report singl factor make invest decis
charl martineau pm univers toronto chart
dsuvia price accord com pani
patient saw rapid sustain point
reduct pain baselin dsuvia
iv take inist delay relief
patient satisfact im pact workflow er
compani data credit suiss estim analysi
charl martineau pm univers toronto one-pag
acceler relief novel approach treat acut pain
strong clinic like commerci profil dsuvia help
captur signific share medic supervis opioid market
valid sublingu platform support doctor regard
benefit patient hospit abil deliv quick pain relief
increas patient throughput save cost
single-dos applic sufentanil formul specif
design mitig risk divers abus support fda/dod
success
dsuvia uptak earn detail launch metric
potenti zalviso nda submiss
commercial-stag compani expect profit
continu basi need like rais cash
assign peak hospit penetr compani total target
disappoint formulari uptak could significantli impact acrx
dsuvia need succeed challeng market gener
altern iv oral opioid continu regulatori risk given
opioid crisi us
dcf-deriv target price incorpor project cash flow
discount rate wacc termin growth rate
fiscal year end decemb thousand except per share data
author report wish acknowledg contribut made
selvakumar nallasami paul singh employe crisil global research
analyt busi divis crisil limit crisil limit
third-parti provid off-shore research servic credit suiss
compani data thomson one credit suiss estim analysi
epssalesepssalesepssalesepssalesc pharmaceut current price feb cap valu upsid downsid charl martineau pm univers toronto bull bear cs scenario
cs view main controversi surround share
outlook
potenti
differenti sublingu approach
allow dsuvia gain traction us even
larg hospit system like slow
adopt given speed take obtain
support avail gener
altern unmet need er
outpati surgeri rapid pain relief
without wait iv allow
dsuvia becom impact product
even hospital/pati share
gain target
compani may file nda zalviso
us late potenti diversifi
dosag market sufentanil
formul us inpati non-
surgic acut pain set approv us
zalviso repres smaller opportun
dzuveo eu like
need out-licens reason
optim given recent success
dsuvia us eu approv
opioid market highli generic
formulari may slower
adopt anoth opioid even
minim overal market
potenti product
also need keep price reason
dsuvia given cost-benefit
iv declin two dose
still wait see full compani plan
us zalviso dzuveo eu
though like small
expect dsuvia differenti rout
administr allow reason
accept committe physician
individu product medic supervis opioid
market gener abl gain accept
quickli smaller network larger network
follow behind provid growth
especi beyond compani
hire sale repres
current assum sale us zalviso eu
dzuveo find
commerci fda approv zalviso
eu partnership dzuveo could provid
increment upsid current number updat
compani pipelin beyond sublingu
sufentanil invest could also
provid increment revenu long-term
base-cas estim
compani data credit suiss estim analysi
charl martineau pm univers toronto dsuvia approv controversi product potenti
address multipl need medic supervis opioid market
roughli equival iv morphin
novel mechan action moa thought lower addict potenti
singl dose pre-fil applic must administ
limit risk divers product
pain relief deliv quickli also last
data suggest threshold analgesia reach within minut
last hour
sublingu rout administr elimin need iv
patient otherwis need one
shorten time pain relief patient without iv
also avoid cost iv administr opioid
potenti impact acut pain manag number set
emerg room post-op follow outpati surgeri
compani data credit suiss estim analysi
dsuvia specif formul mitig risk addict
receptor brain commonli associ opioid respiratori depression/a also
receptor commonli associ addict potenti dsuvia thought avoid act
patient requir one dose despit moderate-to-sever pain demonstr
efficaci drug without major patient clinic trial feel need continu re-dos
patient unlik feel high dose due uniqu mechan action well
one hour administr patient show similar cognit abil compar
one hour often without euphor sed effect commonli seen opioid
compani data credit suiss estim analysi
support govern offici help contribut dsuvia fda
approv novemb
fda commission scott gottlieb publicli defend fda approv dsuvia midst
opioid epidem us
highlight dsuvia differenti compar opioid
commission gottlieb state uniqu aspect dsuvia differenti new formul
sufentanil sufentanil product way consist population-bas
consider fit overal drug armamentarium
furthermor state address controversi around approv potenti risk
approv patient exist treatment option provid adequ analgesia
us depart defens dod also support dsuvia develop
dod provid financi support acelrx develop dsuvia
potenti treat acut pain battlefield without need iv appeal militari
sinc dsuvia approv commission gottlieb said dsuvia approv strictli
potenti applic battlefield prioriti product militari
compani data credit suiss estim analysi
charl martineau pm univers toronto risk evalu mitig strategi rem program help
restrict distribut certifi facil minim safeti concern
compani data credit suiss estim analysi
physician expert fda advisori committe member suggest
dsuvia harder divert iv oral opioid
dsuvia harder divert due single-dos tamper-evid packag non-retract
discret applic restrict distribut bio-adhes keep tablet place quick
tamper-evid packag lack wastag make divers even one dose readili appar unlik liquid opioid
small dose siphon syring pill taken larg bottl
fda advisori committe meet novemb panel doctor fda
state dsuvia unlik increas aberr behavior/diversion/abuse/addict
advisori committe member concern abus divers hard steal single-
main concern drop tablet multipl studi show zero drop tablet physician train
packag instruct help mitig risk
compani data credit suiss estim analysi
charl martineau pm univers toronto uniqu sublingu rout administr provid dsuvia
pain relief occur within min hr
dsuvia sufentanil exist dissolv
tablet single-dos applic
sublingu approach ensur rapid drug deliveri
standard dose contain singl pack
use significantli reduc wait time pain relief
minim dosag error divers risk
sufentanil also benefici attribut
could enhanc uptak market
sufentanil easi administ given triag
reduc time patient feel relief hour minut
unlik iv opioid patient need continu
re-dos heavili monitor nurs
addit despit time potent
fentanyl sufentanil thought activ receptor
brain associ respiratori depress
acrx formul sufentanil gain
valid er doc anesthesiologist
mani consid safeti profil superior iv morphin
efficaci dose roughli equival
iv morphin
compani data credit suiss estim analysi
acut pain manag emerg room set
manag moderate-to-sever acut pain emerg depart major market us
us visit made ed yearli moderate-to-sever acut pain
close patient visit per year current receiv iv opioid pain er alon
averag cost singl dose iv opioid iv initi alon
morphin commonli administ iv opioid follow hydromorphon fentanyl
comparison high cost actual administ opioid drug use gener cost around
com ponent iv dose
breakdown er patient visit
per dose
compani data aha quintilesim credit suiss estim analysi
current standard treat acut pain also often caus crowd
er lower patient satisfact pressur hospit
mani condit adult adult come emerg room pain-rel
control pain faster without delay during/aft administr paramount increas patient
satisfact improv capac emerg room see patient drive increas revenu
administr iv medic expens somewhat difficult depend patient
time need gather materi place iv increas amount time patient need
spend er also neg effect patient satisfact
iv opioid often deliv hospit non-standard dose
increas nurs time need wast leftov product reduc possibl divers
nearli half hospit in believ patient top problem
iv take inist delay relief
compani data credit suiss estim analysi
standard-of-car treat pain caus delay treatment
treatment acut pain usual involv first give patient oral painkil sometim
opioid triag nurs doctor abl see er run tests/x-ray
glass water need take oral painkil caus wait potenti surgeri occur due surgeon
prefer patient stomach empti oper reduc risk complic
dsuvia avoid dissolv sublingu provid rapid pain relief without go stomach
median time triag iv access patient rang hour three hour
access control substanc like morphin hospit two nurs must enter biometr secur room one
nurs must monitor nurs prepar morphin dosag ensur none divert
caus delay hospit multipl nurs tie attend one patient patient volum
increas number er depart decreas workflow neg affect
revenu lost year
compani data credit suiss estim analysi
dsuvia also hold potenti use post-op set improv
patient satisfact lower increas patient throughput
current outpati procedur yearli us moderate-
dsuvia target popul eventu expans use beyond er
expect potenti uptak market well start er seen initi benefit
expert state abil patient walk around cognit awar post-surgeri big
benefit patient famili satisfact oppos remain stationari next iv
expert spoken also said would feel comfort discharg patient
minut give dsuvia compar minimum minut iv/or
compani data credit suiss estim analysi
charl martineau pm univers toronto anoth opioid crisi us lack iv opioid hospit
physician spoken reiter issu
deal given shortag steril
inject chief among iv opioid
result doctor given higher non-standard dosag iv
opioid use patient
increas risk patient given much littl
iv opioid sinc standard dose morphin must
measur hand also increas divers risk
combin variabl uptak iv opioid patient also
lead risk patient either given enough pain relief
much drug risk respiratori depress
dsuvia pois fill void iv opioid left
dsuvia standard dose equal iv morphin lower
list price vs total cost administ morphin
intraven optim uptak current market environ
clinic trial also shown uptak efficaci safeti
sublingu sufentanil vari much age weight fact
reiter doctor practic
compani data credit suiss estim analysi
dsuvia show efficaci reduc pain rapidli phase trial
phase studi random double-blind placebo-control trial
studi evalu safeti efficaci dsuvia versu placebo patient age acut
post-operative pain pain intens scale abdomin surgeri studi
patient dose dsuvia mcg placebo need minimum minut dose
morphin sulfat mg iv avail rescu medic
among endpoint time-weight pain intens differ baselin hour hour
primari endpoint
dsuvia show clinic statist signific efficaci placebo
patient use tablet less across period patient dsuvia group need
rescu medic within first hour vs placebo group
patient saw rapid sustain point
reduct pain baselin
patient wait averag hour
dose maxim um daili fda label
compani data credit suiss estim analysi
dsuvia superior safeti profil compar standard
compar typic opioid dsuvia lower rate advers event clinic trial level
mcg daili dose includ lower rate respiratori depress unlik opioid
wherea opioid like morphin fentanyl carri increas risk respiratori depress possibl result death
dsuvia even administ level maximum daili recommend dose gener show lower risk
expert spoken use dsuvia state seen respiratori depress patient gener
see lower rate nausea/vomit well compar iv opioid
furthermor label state safe use patient mild-to-moder renal insuffici unlik opioid label
limit differ advers reaction rate dsuvia placebo phase
discontinu due advers event actual occur less dsuvia-tr patient patient drop
receiv dsuvia vs patient drop receiv placebo studi
advers reaction dsuvia sim ilar placebo
compani data credit suiss estim analysi
convers er physician highlight interest dsuvia lower
cost increas patient throughput satisfact
zofran oral disintegr tablet treat nausea vomit reduc iv-usag er dsuvia impact
could similar
patient come er end get hospit cut iv use would lead huge reduct
nurs take minut place iv remov time even patient huge cost benefit
requir one nurs retriev dsuvia unlik iv medic need two nurs
mandat get peopl pain control within hour difficult real world
give oral pain medic water could delay time surgeri one need
elderli patient alway good iv access im shot alway option due blood thinner
dosag problem evid opioid tri give littl possibl best pain relief
liquid opioid easiest divert nurs abl give half dose put rest anoth syring
hard get dsuvia applic someon tri would appar sinc patient would get pain relief
see patients/day get narcot pain medicin would elig dsuvia other
may arriv iv alreadi place clearli need admiss long-term pain control
compani data credit suiss estim analysi
could post-op set
deliv good analgesia good safeti profil sensit need nurs
steadi uptak dose monitor without wast nurs time efficaci importantli safe
divers risk low pill bind tongu singl packag unlik would get high one dose dose would
like disintegr mess packag devic
walk around post-op import cognit function analgesia winner winner
crux argument long take put actual iv needl find vein gather equip
scan medic administ discard etc
wast drug need second nurs
happi paramount hcap score make sure patient happi import effici argument
morphin import get iv take patient give bad review devast
easier get smaller hospit satisfact score import bigger hospit slower
post-op patient would get morphin next month wouldnt chang mind even shortag
compani data credit suiss estim analysi
focus commerci strategi initi target high-volum
center histori earli adopt make sens us
small concentr salesforc combin solid target strategi allow dsuvia
gain reason uptak time-frame
compani plan initi target hospit expand hospit peak
compris er patient visit per year current receiv iv opioid well outpati surgeri visit
initi uptak may gradual potenti peak sale dsuvia/sufentanil
focus resourc late feb launch may expand salesforc beyond also target potenti
use dsuvia first-respond point futur
pediatr studi tent plan formul compani sufentanil call zalviso alreadi approv
eu could provid increment boost sale approv us pediatr use
compani data credit suiss estim analysi
dsuvia commerci uptak main driver stock
although hospit market take time penetr
compani state disclos formulari win sale gain
formulari win end initi key metric first quarter dsuvia launch
acceler sale rep hire also depend pace formulari accept end-of-year plan
target potenti acceler uptak compani expect
like start disclos unit reorder rate time reorder experienc initi launch late feb
semi-autom product facil readi project lower cost improv gross margin
current slate work three wholesal includ big plu
depart defens
compani work big gpo final contract yet typic discount
big hospit chain also bilater agreement bigger discount given typic gpo
charl martineau pm univers toronto dsuvia uptak main driver success acelrx
compani sale thousand
assum slow uptak peak sale
also assum eros start given potenti increas brand gener
competit
compani data credit suiss estim analysi
agreement revenuecontract charl martineau pm univers toronto zalviso
zalviso formul sufentanil acelrx asset
zalviso drug/devic combin product
design deliv mcg sufentanil
target outpati surgeri
visit per year well inpati
product phase sinc
compani receiv issu
compani first focu launch dsuvia
move forward zalviso
pediatr studi plan
possibl expand use pediatr set
approv eu state eea countri
unlik dsuvia zalviso self-administ
commerci acrx eu license
grnenthal start expand
receiv royalti
sale ramp date slow
eu gain traction
collabor revenu expect
dsuvia name dzuveo approv eu sinc june commerci
discuss possibl partners/manufactur main hurdl like eur price
compani data credit suiss estim analysi
commercial-stag compani expect profit continu basi
highli leverag success dsuvia
assign peak hospit penetr rate target hospit dsuvia risk certain
hospit pharmaci committe accept product
salesforc current small increment hire plan beyond
opioid epidem remain major public health issu us could limit physician/hospit accept product
dsuvia launch challeng market mani brand gener competitor
need invest heavili commerci infrastructur promot product also medic profession
support program off-set risk associ improp use opioid
expect slow uptak product acut pain space given presenc multipl gener competitor although
remain commerci opportun limit us zalviso eu dzuveo littl market
futur commerci success approv us zalviso may depend addit pediatr studi compani
plan time-frame given receiv lack uptak eu
eu dzuveo approv juli current search partner commercialize/manufactur
product howev even commerci upsid could cap similar eu zalviso
suffici cash hand fund current activ assum need
rais addit cash point latest
compani data credit suiss estim analysi
believ dcf-base valuat best captur
evolut acrx revenu mix long-term outlook
project cash flow assum
discount rate significantli higher us major
pharma large-cap specialti pharma compani
compani data credit suiss estim analysi
perpetu termin valu equiti charl martineau pm univers toronto compani overview
acelrx specialti compani focus
develop innov therapi treatment acut pain
acelrx specialti pharma compani focus develop commerci
innov therapi treatment acut pain medic supervis set
found thoma schreck pamela palmer headquart redwood citi ca
incorpor surx inc delawar juli subsequ chang name acelrx
pharmaceut august ipo februari
primari product dsuvia sufentanil treatment moderate-to-sever acut pain
novemb dsuvia approv fda
approv europ dzuveo june look european partner commerci
acelrx product includ zalviso also treatment moderate-to-sever acut pain
nda resubmiss time evalu follow earlier complet respons letter
launch europ april acelrx partner grnenthal
pipelin product current depriorit order focu dsuvia approv launch
compani data credit suiss estim analysi
co-found
ceo xenoport biopharmaceut compani
focus develop treatment
svp sale market reliant pharmaceut
began career novarti sale oper
director ucsf pain center advanc research
educ gain extens experi
treatment pain
focus improv pain manag
cfo commerci stage biotech compani
cfo unilab
began career pricewaterhousecoop
held sever posit includ product develop
vice-president medic devic engin anesiva inc
vice-president manufactur devic develop algorx
charl martineau pm univers toronto detail descript acelrx senior manag
co-found
mr angotti appoint ceo member compani board director march prior
held posit ceo xenoport inc senior vice president-sal market reliant
acquir gsk work sale oper novarti mr angotti earn
bachelor scienc concentr busi manag cornel univers
master busi administr honor columbia univers
dr palmer serv director chief medic offic sinc co-found compani juli
gain extens experi treatment pain tenur director ucsf pain
center advanc research educ paincar prior paincar
medic director ucsf pain manag centr dr palmer work faculti
member ucsf conduct research basic scienc mechan pain transmiss
co-found omero corpor biopharma compani develop small-molecul protein
therapeut aim improv pain manag dr palmer receiv medic degre doctor
neurosci stanford univers continu ucsf anesthesia resid
mr asadorian appoint cfo august year financ strategi corpor
develop experi prior join acelrx mr asadorian serv cfo inc publicli
trade commercial-stag biotechnolog compani prior serv cfo
unilab privat equity-own medic diagnost compani mr asadorian start
career pricewaterhousecoop partner transact servic group
hold bachelor scienc busi administr degre xavier univers master
busi administr degre univers manchest uk
mr hamel serv chief develop offic sinc septemb prior join acelrx mr hamel
enjoy tenur alza corpor held sever posit includ product develop
manag director project manag execut director oral product develop vice presid
oral product develop among respons mr hamel led develop extended-releas
tablet provid specif concentr drug specif time day mr hamel hold bachelor
scienc biolog univers michigan
mr dasu serv chief engin offic sinc septemb prior join aceclrx mr dasu
serv vice presid medic devic engin anesiva inc vice presid manufactur
devic develop emerg pain manag compani merg
corgentech inc decemb mr dasu hold bachelor engin chemic engin
univers mangalor india master scienc chemic engin univers tulsa
charl martineau pm univers toronto acelrx board director
board director
chairman board director
criteria independ criteria applic nasdaq stock market rule
acelrx compens execut offic director
valu
compani data credit suiss estim analysi
compani data credit suiss estim analysi
agreement agreement charl martineau pm univers toronto incom statement
compani data credit suiss estim analysi
incom incom incom expens expens royalty-rel liabil loss tax expens profit average share calcul dilut analysisgross tax tax incom changestot charl martineau pm univers toronto balanc sheet
compani data credit suiss estim analysi
asset cash term receiv expens current current equip term tax stockhold equitycurr liabil account debt current revenu current relat sale futur royalti current current rent net current debt net current revenu net current relat sale futur royalti net current put option equitycommon stock par paid-in comprehens incom stockhold liabil stockhold charl martineau pm univers toronto statement
compani data credit suiss estim analysi
activ net profit/ royalti revenu relat royalti interest expens liabil relat royalti interest expens relat debt put option pipe warrant extinguish dispos impair properti impair oper asset liabil account expens cash use oper activ purchas properti matur cash use invest activ net proce sale futur issuanc common stock equiti issuanc long-term long-term debt modif transact proce issuanc common stock equiti cash use financ decreas increas cash cash cash equival begin cash equival end charl martineau pm univers toronto compani mention price inc oq outperform tp amr oq anesiva oq cah collegium pharm coll oq glaxosmithklin plc gsk mck mochida pharm novarti novn omer oq pdli oq pfe pricewaterhousecoop aarata unlist unilab xenoport inc zynerba pharm zyne oq disclosur appendix analyst certif vamil divan md certifi view express report accur reflect person view subject compani secur part compens directli indirectli relat specif recommend view express report price rate histori cah cah close price target price date us us rate nr signifi initi assumpt coverag ratedoutperform price rate histori mck mck close price target price date us us rate nr signifi initi assumpt coverag ratedneutralunderperform price rate histori pfe pfe close price target price date us us rate signifi initi assumpt coverag outperformneutr decemb analyst stock rate defin follow outperform stock total return expect outperform relev benchmark next month neutral stock total return expect line relev benchmark next month under-perform stock total return expect under-perform relev benchmark next month relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers consist compani cover analyst within relev sector outperform repres attract neutral less attract underperform least attract invest opportun octob canadian well european rate base stock total return rel analyst coverag univers consist compani cover analyst within relev sector outperform repres attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan australia rate base stock total return rel averag total return relev countri region benchmark india bse sensex index prior octob canadian rate base stock absolut total return potenti current share price rel attract stock total return potenti within analyst coverag univers australian new zealand stock expect total return calcul includ roll dividend yield outperform rate assign greater equal under-perform less equal neutral may assign overlap rate rang allow analyst assign rate put context associ risk prior may rang outperform under-perform rate overlap neutral threshold oper juli restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun includ invest recommend cours credit suiss engag invest bank transact certain circumst rate nr credit suiss equiti research invest rate view stock secur relat compani time cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view equiti secur compani relat product volatil indic stock defin volatil stock price move month least past month analyst expect signific volatil go forward analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat sector rel group histor fundament and/or valuat overweight analyst expect sector fundament and/or valuat favor next month market weight analyst expect sector fundament and/or valuat neutral next month underweight analyst expect sector fundament and/or valuat cautiou next month analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector credit suiss distribut stock rate bank client global rate distribut rate versu univers bank client outperform/buy bank client neutral/hold bank client underperform/sel bank client restrict purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform close correspond buy hold sell respect howev mean stock rate determin rel basi pleas refer definit investor decis buy sell secur base invest object current hold individu factor import global disclosur credit suiss research report made avail client proprietari research portal cs credit suiss research product may also made avail third-parti vendor altern electron mean conveni certain research product made avail cs servic provid credit suiss analyst client may depend specif client prefer regard frequenc manner receiv commun client risk profil invest size scope overal client relationship charl martineau pm univers toronto firm well legal regulatori constraint access credit suiss research entitl receiv time manner pleas contact sale repres go http //plu credit-suiss com credit suiss polici updat research report deem appropri base develop subject compani sector market may materi impact research view opinion state herein credit suiss polici publish invest research imparti independ clear fair mislead detail pleas refer credit suiss polici manag conflict interest connect invest research http //www credit-suiss com/sites/disclaimers-ib/en/managing-conflict html credit suiss provid tax advic statement herein regard us feder tax intend written use use taxpay purpos avoid penalti credit suiss decid enter busi relationship compani credit suiss determin involv develop manufactur acquisit anti-personnel mine cluster munit credit suiss posit issu pleas see http //www credit-suiss com/media/assets/corporate/docs/about-us/responsibility/banking/policy-summaries-en pdf analyst respons prepar research report receiv compens base upon variou factor includ credit suiss total revenu portion gener credit suiss invest bank activ target price rate valuat methodolog risk month inc oq method target price drive outperform rate base dcf valuat use discount rate forecast discount cash flow termin growth rate thereaft base peak dsuvia penetr er outpati surgeri market risk risk target price outperform rate follow commercial-stag specialti pharmaceut compani expect profit continu basi need like rais cash point late disappoint accept dsuvia hospit pharmaci therapeut committe physician could significantli impact outlook given nearli revenu expect dsuvia pleas refer firm disclosur websit http //rave credit-suiss com/disclosures/view/selectarch definit abbrevi typic use target price method risk section compani mention section full compani name credit suiss current within past month follow invest bank client oq pfe cah credit suiss provid invest bank servic subject compani oq pfe cah within past month within last month credit suiss receiv compens non-invest bank servic product follow issuer pfe credit suiss manag co-manag public offer secur subject compani oq pfe within past month within past month credit suiss receiv compens invest bank servic follow issuer oq pfe cah credit suiss expect receiv intend seek invest bank relat compens subject compani oq pfe cah within next month credit suiss current within past month follow issuer client servic provid non-investment-bank securities-rel pfe credit suiss current within past month follow issuer client servic provid non-investment-bank non securities-rel pfe credit suiss member credit suiss group market maker liquid provid secur follow subject issuer oq cah mck pfe member credit suiss group parti agreement may provid servic set section annex direct european parliament council mifid servic subject issuer oq pfe cah within past month research analyst contribut content research report household member employ hold long posit equiti secur long posit option compani pfe date time product dissemin histori recommend subject compani featur report dissemin within past month pleas refer link import region disclosur singapor recipi contact credit suiss ag singapor branch matter aris research report analyst involv prepar report may particip event host subject compani includ site visit credit suiss accept permit analyst accept payment reimburs travel expens associ event restrict certain canadian secur indic follow abbrevi nv -- non-vot share rv -- restrict vote share sv -- subordin vote share individu receiv report canadian invest dealer affili credit suiss advis report may contain regulatori disclosur non-affili canadian invest dealer would requir make report credit suiss secur canada inc polici procedur regard dissemin equiti research pleas visit http //www credit-suiss com/sites/disclaimers-ib/en/canada-research-polici html princip guarante case equiti equiti price variabl commiss commiss rate amount agre custom set account time research report author credit suiss secur usa llc vamil divan md uy inanc caner import disclosur regard compani subject report avail call import disclosur except valuat methodolog risk discuss also avail credit suiss disclosur websit http //rave credit-suiss com/disclosur valuat methodolog risk associ recommend price target rate referenc report pleas refer disclosur section recent report regard subject compani charl martineau pm univers toronto report produc subsidiari affili credit suiss oper global market divis inform structur pleas use follow link http //www credit-suiss com/who-we-ar report may contain materi direct intend distribut use person entiti citizen resid locat local state countri jurisdict distribut public avail use would contrari law regul would subject credit suiss affili cs registr licens requir within jurisdict materi present report unless specif indic otherwis copyright cs none materi content copi may alter way transmit copi distribut parti without prior express written permiss cs trademark servic mark logo use report trademark servic mark regist trademark servic mark cs affili inform tool materi present report provid inform purpos use consid offer solicit offer sell buy subscrib secur financi instrument cs may taken step ensur secur refer report suitabl particular investor cs treat recipi report custom virtu receiv report invest servic contain refer report may suitabl recommend consult independ invest advisor doubt invest invest servic noth report constitut invest legal account tax advic represent invest strategi suitabl appropri individu circumst otherwis constitut person recommend cs advis tax consequ invest advis contact independ tax advis pleas note particular base level taxat may chang inform opinion present report obtain deriv sourc believ cs reliabl cs make represent accuraci complet cs accept liabil loss aris use materi present report except exclus liabil appli extent liabil aris specif statut regul applic cs report reli upon substitut exercis independ judgment cs may issu may futur issu commun inconsist reach differ conclus inform present report commun reflect differ assumpt view analyt method analyst prepar cs oblig ensur commun brought attent recipi report invest refer report offer sole singl entiti case invest sole cs associ cs cs may market maker invest past perform taken indic guarante futur perform represent warranti express impli made regard futur perform inform opinion estim contain report reflect judgment origin date public cs subject chang without notic price valu incom secur financi instrument mention report fall well rise valu secur financi instrument subject exchang rate fluctuat may posit advers effect price incom secur financi instrument investor secur adr valu influenc currenc volatil effect assum risk structur secur complex instrument typic involv high degre risk intend sale sophist investor capabl understand assum risk involv market valu structur secur may affect chang econom financi polit factor includ limit spot forward interest exchang rate time matur market condit volatil credit qualiti issuer refer issuer investor interest purchas structur product conduct investig analysi product consult profession advis risk involv make purchas invest discuss report may high level volatil high volatil invest may experi sudden larg fall valu caus loss invest realis loss may equal origin invest inde case invest potenti loss may exceed amount initi invest circumst may requir pay money support loss incom yield invest may fluctuat consequ initi capit paid make invest may use part incom yield invest may readili realis may difficult sell realis invest similarli may prove difficult obtain reliabl inform valu risk invest expos report may provid address contain hyperlink websit except extent report refer websit materi cs cs review site take respons content contain therein address hyperlink includ address hyperlink cs websit materi provid sole conveni inform content websit way form part document access websit follow link report cs websit shall risk report issu distribut european union except switzerland credit suiss secur europ limit one squar london england authoris prudenti regul author regul financi conduct author prudenti regul author germani credit suiss deutschland aktiengesellschaft regul bundesanstalt fuer finanzdienstleistungsaufsicht bafin ed state canada credit suiss secur usa llc switzerland credit suiss ag brazil banco de investimento credit suiss brasil affili mexico banco credit suiss mxico institucin de banca mltipl grupo financiero credit suiss mxico de bolsa credit suiss mxico de grupo financiero credit suiss mxico credit suiss mexico document prepar inform purpos exclus distribut mexico institut investor credit suiss mexico respons onward distribut report non-institut investor third parti author report receiv payment compens entiti compani relev credit suiss group compani employ japan credit suiss secur japan limit financi instrument firm director-gener kanto local financ bureau kinsho member japan secur dealer associ financi futur associ japan japan invest advis associ type ii financi instrument firm associ hong kong credit suiss hong kong limit australia credit suiss equiti australia limit thailand credit suiss secur thailand limit regul offic secur exchang commiss thailand regist address abdulrahim place floor rama iv silom bangrak thailand tel malaysia credit suiss secur malaysia sdn bhd singapor credit suiss ag singapor branch india credit suiss secur india privat limit cin regul secur exchang board india research analyst registr inh stock broker registr regist address floor ceejay hous dr worli mumbai india t- south korea credit suiss secur europ limit seoul branch taiwan credit suiss ag taipei secur branch indonesia pt credit suiss sekurita indonesia philippin credit suiss secur philippin inc elsewher world relev authoris affili addit region disclaim australia credit suiss secur europ limit cssel credit suiss intern csi authoris prudenti regul author regul financi conduct author fca prudenti regul author uk law differ australian cssel csi hold australian financi servic licenc afsl exempt requir hold afsl corpor act cth corpor act respect financi servic provid australian wholesal client within mean section corpor act hereinaft refer financi servic materi distribut retail client direct exclus credit suiss profession client elig counterparti defin fca wholesal client defin section corpor act credit suiss hong kong limit cshk licens regul secur futur commiss hong kong law hong kong differ australian law cshkl hold afsl exempt requir hold afsl corpor act respect provid financi servic invest bank servic ed state provid credit suiss secur usa llc affili credit suiss group cssu regul ed state secur exchang commiss ed state law differ australian law cssu hold afsl exempt requir hold afsl corpor act respect provid financi servic credit suiss asset manag llc csam authoris secur exchang commiss us law differ australian law csam hold afsl exempt requir hold afsl corpor act respect provid financi servic materi provid sole institut account defin finra rule elig contract particip defin us commod exchang act credit suiss equiti australia limit abn cseal afsl holder australia afsl malaysia research provid resid malaysia authoris head research credit suiss secur malaysia sdn bhd direct queri singapor report prepar issu distribut singapor institut investor accredit investor expert investor defin financi advis regul also distribut credit suiss ag singapor branch oversea investor defin financi advis regul credit suiss ag singapor branch may distribut report produc foreign entiti affili pursuant arrang regul financi advis regul singapor recipi contact credit suiss ag singapor branch matter aris connect report virtu statu institut investor accredit investor expert investor oversea investor credit suiss ag singapor branch exempt compli certain complianc requir financi advis act chapter singapor faa financi advis regul relev notic guidelin issu thereund respect financi advisori servic credit suiss ag singapor branch may provid eu report produc subsidiari affili credit suiss oper global market divis jurisdict cs alreadi regist licens trade secur transact effect accord applic secur legisl vari jurisdict jurisdict may requir trade made accord applic exempt registr licens requir materi issu distribut cssu member nyse finra sipc nfa cssu accept respons content client contact analyst execut transact credit suiss subsidiari affili home jurisdict unless govern law permit otherwis pleas note research origin prepar issu cs distribut market profession institut investor custom recipi market profession institut investor custom cs seek advic independ financi advisor prior take invest decis base report necessari explan content research may relat invest servic person outsid uk matter authoris prudenti regul author regul financi conduct author prudenti regul author respect protect prudenti regul author financi conduct author privat custom and/or uk compens scheme may avail detail may case avail upon request respect report cs may provid variou servic us municip entiti oblig person municip includ suggest individu transact trade enter transact servic cs provid municip view advic within mean section dodd-frank wall street reform consum protect act cs provid servic relat inform sole arm length basi advisor fiduciari municip connect provis servic agreement direct indirect municip includ offici manag employe agent thereof cs cs provid advic municip municip consult financi account legal advisor regard servic provid cs addit cs act direct indirect compens solicit municip behalf unaffili broker dealer municip secur dealer municip advisor invest advis purpos obtain retain engag municip connect municip financi product issuanc municip secur invest advis provid invest advisori servic behalf municip report distribut financi institut credit suiss ag affili financi institut sole respons distribut client institut contact institut effect transact secur mention report requir inform report constitut invest advic credit suiss client distribut financi institut neither credit suiss ag affili respect offic director employe accept liabil whatsoev direct consequenti loss aris use report content princip guarante commiss commiss rate amount agre custom set account time inform commun provid herein otherwis intend constru recommend within mean us depart labor final regul defin invest advic purpos employe retir incom secur act amend section intern revenu code amend inform provid herein intend gener inform constru provid invest advic imparti otherwis copyright credit suiss ag and/or affili right reserv invest princip bond erod depend sale price market price addit bond invest princip erod due chang redempt amount requir invest instrument purchas non-list japanes fix incom secur japanes govern bond japanes municip bond japanes govern guarante bond japanes corpor bond cs seller request pay purchas price charl martineau pm univers toronto
